CVS Beats on Q3, Raises 2026 EPS and Cash Flow Guidance
CVS sits 32% above its 52-week low of $69.51 on elevated volume (2.4× avg).
Summary
CVS reported Q3 revenue of $108.4 billion (up 5.4%) and Adjusted EPS of $2.09, then raised full-year 2026 Adjusted EPS guidance to at least $8.20 and operating cash flow guidance to at least $15.5 billion.
Key Events · Earnings and Guidance · CVS
-
Q3 Revenue Up 5.4% to $108.4B
Total revenues rose to $108.4 billion from $102.9 billion, driven by growth in Health Services and Health Care Benefits.
-
Full-Year Guidance Raised Across the Board
GAAP diluted EPS guidance to at least $6.98 from $6.84-$7.04, Adjusted EPS to at least $8.20 from $7.90-$8.10, and cash flow from operations to at least $15.5 billion from at least $11.5 billion.
-
Aetna Margin Recovery Drives the Beat
Health Care Benefits adjusted operating income rose to $912 million from $314 million as the medical benefit ratio improved 150 bps to 91.3%.
-
Cash Generation Already at $15.3B YTD
Year-to-date cash flow from operations of $15.3 billion versus $7.2 billion in the prior-year period.
Analysis · CVS · Trade & Services
The headline is the guidance raise: GAAP diluted EPS to at least $6.98 (from $6.84-$7.04), Adjusted EPS to at least $8.20 (from $7.90-$8.10), and cash flow from operations to at least $15.5 billion from at least $11.5 billion. That cash-flow lift is the standout — roughly $4 billion more than previously guided — and it comes with year-to-date operating cash flow already at $15.3 billion. Aetna is the engine: Health Care Benefits adjusted operating income jumped to $912 million from $314 million as the medical benefit ratio improved 150 basis points to 91.3%, evidence the margin recovery plan is working. Management still flagged elevated cost trends and macro headwinds for the rest of the year, so the raise is not a blank check. This lands one day after reports that CVS is discussing a spin-off of its retail pharmacy division, and a stronger balance sheet and cash generation strengthen its hand in any separation.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVS was trading at $91.49 on NYSE in the Trade & Services sector, with a market capitalization of approximately $116.9B. The 52-week trading range was $69.51 to $110.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.